This trial is a Phase II study of Cabazitaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). The study is designed to determine if cabazitaxel improves progression free survival (PFS) or overall survival (OS). Eligible patients must have been previously treated and progressed under docetaxel or abiraterone regimen.
1 Primary · 7 Secondary · Reporting Duration: hrough study completion, an average of 1 year
214 Total Participants · 2 Treatment Groups
Primary Treatment: Cabazitaxel plus prednisone · No Placebo Group · Phase 2
Age 18+ · Male Participants · 7 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: